Concurrent targeting of MAP3K3 and BRD4 by miR-3140-3p overcomes acquired resistance to BET inhibitors in neuroblastoma cells

• Główni autorzy: Chang Liu (Autor), Yasuyuki Gen (Autor), Kousuke Tanimoto (Autor), Tomoki Muramatsu (Autor), Jun Inoue (Autor), Johji Inazawa (Autor)
• Format: Książka
• Wydane: Elsevier, 2021-09-01T00:00:00Z.
• Hasła przedmiotowe: article
• Dostęp online: Connect to this object online.

Neuroblastoma (NB) harboring MYCN amplification is a refractory disease with a poor prognosis. As BRD4, an epigenetic reader belonging to the bromodomain and extra terminal domain (BET) family, drives transcription of MYCN in NB cells, BET inhibitors (BETis) are considered useful for NB therapy. How...